Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 917156, 10 pages
http://dx.doi.org/10.1155/2015/917156
Research Article

Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress

1Molecular Pharmacology Unit, Department of Chemistry and Applied Biosciences, ETH Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
2International Neuroscience Institute (INI) Hannover, Rudolf-Pichlmayr-Strasse 4, 30625 Hannover, Germany
3Medical Research Centre (MRC), Ain Shams University Hospitals, Abassia, Cairo 11591, Egypt
4Institute of Pharmacology and Toxicology, Department of Medicine, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland

Received 20 August 2015; Accepted 12 November 2015

Academic Editor: Grazia D’Onofrio

Copyright © 2015 Said AbdAlla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Scully, “Demography: to the limit,” Nature, vol. 492, no. 7427, pp. S2–S3, 2012. View at Google Scholar · View at Scopus
  2. A. Abbott, “Dementia: a problem for our age,” Nature, vol. 475, no. 7355, pp. S2–S4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Marcello, F. Gardoni, and M. Di Luca, “Alzheimer's disease and modern lifestyle: what is the role of stress?” Journal of Neurochemistry, vol. 134, no. 5, pp. 795–798, 2015. View at Publisher · View at Google Scholar
  4. P. Willner, A. Towell, D. Sampson, S. Sophokleous, and R. Muscat, “Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant,” Psychopharmacology, vol. 93, no. 3, pp. 358–364, 1987. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Cuadrado-Tejedor, A. Ricobaraza, J. Del Río et al., “Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation,” Behavioural Brain Research, vol. 220, no. 2, pp. 338–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Alonso, G. Griebel, G. Pavone, J. Stemmelin, G. Le Fur, and P. Soubrié, “Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression,” Molecular Psychiatry, vol. 9, no. 3, pp. 278–286, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Qiao, S. C. An, W. Ren, and X. M. Ma, “Progressive alterations of hippocampal CA3-CA1 synapses in an animal model of depression,” Behavioural Brain Research, vol. 275, pp. 191–200, 2014. View at Publisher · View at Google Scholar
  8. Y. A. El-faramawy, M. H. El-banouby, P. Sergeev, A. K. Mortagy, M. S. Amer, and A. M. Abdel-tawab, “Changes in glutamate decarboxylase enzyme activity and tau-protein phosphorylation in the hippocampus of old rats exposed to chronic mild stress: reversal with the neuronal nitric oxide synthase inhibitor 7-nitroindazole,” Pharmacology Biochemistry and Behavior, vol. 91, no. 3, pp. 339–344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. AbdAlla, H. Lother, A. El Missiry et al., “Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease,” Journal of Biological Chemistry, vol. 284, no. 10, pp. 6554–6565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Cuadrado-Tejedor, A. Ricobaraza, D. Frechilla, R. Franco, A. Pérez-Mediavilla, and A. Garcia-Osta, “Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in TG2576 mice,” Journal of Alzheimer's Disease, vol. 28, no. 3, pp. 567–578, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Cuadrado-Tejedor and A. Garcia-Osta, “Chronic mild stress assay leading to early onset and propagation of Alzheimer's disease phenotype in mouse models,” in Systems Biology of Alzheimer's Disease, vol. 1303 of Methods in Molecular Biology, pp. 241–246, Springer, New York, NY, USA, 2016. View at Publisher · View at Google Scholar
  12. A. Briones, S. Gagno, E. Martisova et al., “Stress-induced anhedonia is associated with an increase in Alzheimer's disease-related markers,” British Journal of Pharmacology, vol. 165, no. 4, pp. 897–907, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Doody, R. G. Thomas, M. Farlow et al., “Phase 3 trials of solanezumab for mild-to-moderate alzheimer's disease,” The New England Journal of Medicine, vol. 370, no. 4, pp. 311–321, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Salloway, R. Sperling, N. C. Fox et al., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease,” The New England Journal of Medicine, vol. 370, no. 4, pp. 322–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Karran and J. Hardy, “Antiamyloid therapy for Alzheimer's disease—are we on the right road?” The New England Journal of Medicine, vol. 370, no. 4, pp. 377–378, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. L. Hemming and D. J. Selkoe, “Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor,” Journal of Biological Chemistry, vol. 280, no. 45, pp. 37644–37650, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. E. A. Eckman, S. K. Adams, F. J. Troendle et al., “Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme,” The Journal of Biological Chemistry, vol. 281, no. 41, pp. 30471–30478, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. K. E. Bernstein, Y. Koronyo, B. C. Salumbides et al., “Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 1000–1012, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. Y.-F. Dong, K. Kataoka, Y. Tokutomi et al., “Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease,” The FASEB Journal, vol. 25, no. 9, pp. 2911–2920, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. AbdAlla, A. Langer, X. Fu, and U. Quitterer, “ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease,” International Journal of Molecular Sciences, vol. 14, no. 8, pp. 16917–16942, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Ohrui, N. Tomita, T. Sato-Nakagawa et al., “Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression,” Neurology, vol. 63, no. 7, pp. 1324–1325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Soto, G. A. van Kan, F. Nourhashemi et al., “Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort,” Journal of the American Geriatrics Society, vol. 61, no. 9, pp. 1482–1488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Gao, R. O'Caoimh, L. Healy et al., “Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia,” BMJ Open, vol. 3, no. 7, Article ID e002881, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. R. O'Caoimh, L. Healy, Y. Gao et al., “Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with alzheimer's disease,” Journal of Alzheimer's Disease, vol. 40, no. 3, pp. 595–603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. F. F. de Oliveira, P. H. F. Bertolucci, E. S. Chen, and M. C. Smith, “Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 42, supplement 3, pp. S321–S324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Mei, J. C. Fuscoe, E. K. Lobenhofer, and L. Guo, “Application of microarray-based analysis of gene expression in the field of toxicogenomics,” Methods in Molecular Biology, vol. 597, pp. 227–241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Guo, E. K. Lobenhofer, C. Wang et al., “Rat toxicogenomic study reveals analytical consistency across microarray platforms,” Nature Biotechnology, vol. 24, no. 9, pp. 1162–1169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Yan, X.-B. Sun, H.-Q. Wang et al., “Chronic restraint stress alters the expression and distribution of phosphorylated tau and MAP2 in cortex and hippocampus of rat brain,” Brain Research, vol. 1347, pp. 132–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Couratier, M. Lesort, P. Sindou, F. Esclaire, C. Yardin, and J. Hugon, “Modifications of neuronal phosphorylated τ immunoreactivity induced by NMDA toxicity,” Molecular and Chemical Neuropathology, vol. 27, no. 3, pp. 259–273, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. J. H. Lee, Z. Z. Wei, D. Chen, X. Gu, L. Wei, and S. P. Yu, “A neuroprotective role of the NMDA receptor subunit GluN3A (NR3A) in ischemic stroke of the adult mouse,” American Journal of Physiology—Cell Physiology, vol. 308, no. 7, pp. C570–C577, 2015. View at Publisher · View at Google Scholar
  31. H. Wang, H. Yan, S. Zhang, X. Wei, J. Zheng, and J. Li, “The GluN3A subunit exerts a neuroprotective effect in brain ischemia and the hypoxia process,” American Society for Neurochemistry Neuro, vol. 5, no. 4, pp. 231–242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. K. N. Green, L. M. Billings, B. Roozendaal, J. L. McGaugh, and F. M. LaFerla, “Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer's disease,” Journal of Neuroscience, vol. 26, no. 35, pp. 9047–9056, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. L. M. Barreto-Chaves, I. Anèas, and J. E. Krieger, “Glucocorticoid regulation of angiotensin-converting enzyme in primary culture of adult cardiac fibroblasts,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 280, no. 1, pp. R25–R32, 2001. View at Google Scholar · View at Scopus
  34. Y. Dasarathy, J. J. Lanzillo, and B. L. Fanburg, “Stimulation of bovine pulmonary artery endothelial cell ACE by dexamethasone: involvement of steroid receptors,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 263, no. 6, pp. L645–L649, 1992. View at Google Scholar · View at Scopus
  35. R. S. Fishel, S. Eisenberg, S. Y. Shai, R. A. Redden, K. E. Bernstein, and B. C. Berk, “Glucocorticoids induce angiotensin-converting enzyme expression in vascular smoth muscle,” Hypertension, vol. 25, no. 3, pp. 343–349, 1995. View at Publisher · View at Google Scholar
  36. S. Villapol and J. M. Saavedra, “Neuroprotective effects of angiotensin receptor blockers,” American Journal of Hypertension, vol. 28, no. 3, pp. 289–299, 2015. View at Publisher · View at Google Scholar
  37. M. Tian, D. Zhu, W. Xie, and J. Shi, “Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains,” FEBS Letters, vol. 586, no. 20, pp. 3737–3745, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. Y.-M. Kang, D.-M. Zhang, X.-J. Yu et al., “Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neutrotransmitters and cytokines,” Toxicology and Applied Pharmacology, vol. 274, no. 3, pp. 436–444, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Zhu, J. Shi, Y. Zhang et al., “Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats,” PLoS ONE, vol. 6, no. 1, Article ID e16037, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Liu, S. Liu, Y. Matsumoto et al., “Angiotensin type 1a receptor deficiency decreases amyloid β-protein generation and ameliorates brain amyloid pathology,” Scientific Reports, vol. 5, article 12059, 2015. View at Publisher · View at Google Scholar
  41. N. Glorioso, P. Dessìfulgheri, S. Alagna et al., “Angiotensin converting enzyme inhibition reduces ACTH release due to hypoglycaemia,” Clinical and Experimental Hypertension A, Theory and Practic, vol. 9, no. 2-3, pp. 665–670, 1987. View at Publisher · View at Google Scholar · View at Scopus
  42. X.-Z. Zhang, Y. Quan, and G.-Y. Tang, “Medical genetics-based drug repurposing for Alzheimer's disease,” Brain Research Bulletin, vol. 110, pp. 26–29, 2015. View at Publisher · View at Google Scholar · View at Scopus